25.07.2019 Views

The 10 Companies Booming in Healthcare Sector

Acknowledging the remarkable contribution of the leading companies in the care sector, we bring to you the special issue of “The 10 Companies Booming in Healthcare Sector”. This edition portrays the inspiring stories of the listed pre-eminent organizations that are shaping the future of healthcare through innovation and dedication.

Acknowledging the remarkable contribution of the leading companies in the care sector, we bring to you the special issue of “The 10 Companies Booming in Healthcare Sector”. This edition portrays the inspiring stories of the listed pre-eminent organizations that are shaping the future of healthcare through innovation and dedication.

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

2019 Vol.6/ Issue-2<br />

www.<strong>in</strong>sightscare.com<br />

THE<br />

<strong>10</strong><br />

COMPANIES<br />

BOOMING<br />

IN HEALTHCARE<br />

SECTOR<br />

Dr. John Moller<br />

CEO<br />

NOVOTECH<br />

A Catalyst for Growth and a<br />

Better Tomorrow


THE TOMORROW OF<br />

HEALTHCARE<br />

he landscape of healthcare has noticeably changed compared to what it was a few years ago.<br />

T<strong>The</strong> global expenditure of healthcare has been on a spree, ris<strong>in</strong>g at the rate of 5.7 percent<br />

annually, between the years 2017 to 2022. This growth is driven by various factors <strong>in</strong>clud<strong>in</strong>g<br />

the rise <strong>in</strong> the population of people <strong>in</strong> older age groups, <strong>in</strong>creased chronic disease rates, new demands<br />

of the care receivers and newer approach of care givers, and many more. Based on the scenario of the<br />

global healthcare <strong>in</strong>dustry <strong>in</strong> 2019, we can predict a few possibilities that will drive the market <strong>in</strong> the<br />

years to come.<br />

<strong>The</strong> two big trends that have emerged <strong>in</strong> the past few years are the shift<strong>in</strong>g of this <strong>in</strong>dustry towards<br />

personalized, outcome-based care and the developments <strong>in</strong> diagnostic and preventive care. <strong>The</strong>se<br />

trends will cont<strong>in</strong>ue to ga<strong>in</strong> popularity and many new startups as well as well-settled bus<strong>in</strong>ess players<br />

are seen to focus on them. <strong>The</strong> advancements <strong>in</strong> healthcare have come with huge <strong>in</strong>vestments and<br />

there is a ris<strong>in</strong>g need to br<strong>in</strong>g <strong>in</strong> better solutions at affordable prices. Many new researches and<br />

fund<strong>in</strong>g for drug development and treatments, along with technological advancements, are seen and<br />

are expected to <strong>in</strong>crease further. <strong>The</strong> future holds a promise for various disruptive <strong>in</strong>novations to make<br />

this a reality. We will also owe it to mergers and collaborations among various healthcare and nonhealthcare<br />

organizations to atta<strong>in</strong> f<strong>in</strong>ancial susta<strong>in</strong>ability.<br />

Technological <strong>in</strong>novation is another key factor driv<strong>in</strong>g the steer<strong>in</strong>g of tomorrow for healthcare niche.<br />

With emergence and wide-spread acceptance of developments <strong>in</strong> wearable devices, remote healthcare,<br />

telemedic<strong>in</strong>e, patient management apps, digital healthcare, and more, myriads of companies are seen<br />

to <strong>in</strong>vest <strong>in</strong> these areas. <strong>The</strong> consumer demands have changed with their <strong>in</strong>creased role <strong>in</strong> the system<br />

and therefore, the focus should be shifted to patient engagement and build<strong>in</strong>g of more personal<br />

relationships. Additionally, technologies like AI, VR, 3D pr<strong>in</strong>t<strong>in</strong>g, medical imag<strong>in</strong>g, etc. have entered<br />

the healthcare sector and are assist<strong>in</strong>g the providers <strong>in</strong> offer<strong>in</strong>g more accurate and enhanced care to the<br />

patients.<br />

With <strong>in</strong>crease <strong>in</strong> the number of changes the <strong>in</strong>dustry is witness<strong>in</strong>g, there is <strong>in</strong>crease <strong>in</strong> the need of<br />

regulatory policies and compliances as well. Other than that, patient data has become the new<br />

currency <strong>in</strong> healthcare. Along with this comes the need of cyber-security for protect<strong>in</strong>g the highly<br />

sensitive and critical healthcare data. Additionally, the trend of health food habits and self-care has<br />

grown tremendously. <strong>The</strong> <strong>in</strong>dustry will be focus<strong>in</strong>g on these aspects as well.<br />

<strong>The</strong> stakeholders of healthcare, <strong>in</strong>clud<strong>in</strong>g providers, <strong>in</strong>vestors, and consumers, have newer demands<br />

and the ecosystem is, therefore, shift<strong>in</strong>g towards better and susta<strong>in</strong>able solutions. <strong>The</strong> <strong>in</strong>dustry is<br />

expected to grow further, market as well as development wise. Preventive care, f<strong>in</strong>ancial<br />

susta<strong>in</strong>ability, digitalization, and so many other popular factors may take us towards an enhanced,<br />

affordable, and accessible tomorrow!<br />

Aishwarya Nawandhar<br />

Editor


Editor’s Column


Cover Story<br />

<strong>10</strong><br />

NOVOTECH<br />

A Catalyst for Growth and a Better Tomorrow<br />

Interview with Insights Care<br />

Sanomics<br />

Improv<strong>in</strong>g <strong>Healthcare</strong><br />

with Innovation and<br />

Compassion<br />

16<br />

22<br />

Industry Insight<br />

What Digital Startups<br />

Need To Succeed In <strong>The</strong><br />

<strong>Healthcare</strong> Space<br />

CXO


CONTENTS<br />

24 32 34<br />

David<br />

Health Solutions<br />

Movement as<br />

Medic<strong>in</strong>e<br />

Accutest<br />

Research Laboratories<br />

<strong>The</strong> Preferred CRO<br />

Partner for <strong>Healthcare</strong><br />

<strong>Companies</strong><br />

Sp<strong>in</strong>eMark<br />

Corporation<br />

Transform<strong>in</strong>g Care<br />

Delivery Through<br />

Exceptional Care Services<br />

28<br />

In-house Op<strong>in</strong>ion<br />

Social Media Market<strong>in</strong>g<br />

A Necessary Trend to<br />

Pick for <strong>Healthcare</strong><br />

Professionals<br />

Articles<br />

36<br />

Novel Discoveries<br />

Top Health Tech<br />

Innovations <strong>in</strong> 2019<br />

that are Break<strong>in</strong>g<br />

the Barriers


Market Leaders<br />

Driv<strong>in</strong>g Development<br />

<strong>in</strong> Care Industry<br />

evelopment is a cont<strong>in</strong>uous process <strong>in</strong> any sector. It br<strong>in</strong>gs <strong>in</strong> more comfort, more precision, and more<br />

Denhanced way of liv<strong>in</strong>g. Almost all the <strong>in</strong>dustries have and will cont<strong>in</strong>ue to witness extensive<br />

developments <strong>in</strong> their respective niches and healthcare sector is not aloof of this process. <strong>The</strong> health<br />

and medical <strong>in</strong>dustry has grown through the years with technological and device developments, pharmaceutical<br />

advancements, process enhancement, and more. It owes this to various organizations and people that have<br />

dedicated their resources and expertise to improve several areas of healthcare.<br />

Acknowledg<strong>in</strong>g the remarkable contribution of the lead<strong>in</strong>g companies <strong>in</strong> the care sector, we br<strong>in</strong>g to you the<br />

special issue of “<strong>The</strong> <strong>10</strong> <strong>Companies</strong> <strong>Boom<strong>in</strong>g</strong> <strong>in</strong> <strong>Healthcare</strong> <strong>Sector</strong>”. This edition portrays the <strong>in</strong>spir<strong>in</strong>g<br />

stories of the listed pre-em<strong>in</strong>ent organizations that are shap<strong>in</strong>g the future of healthcare through <strong>in</strong>novation and<br />

dedication.<br />

Featured on the cover is the <strong>in</strong>ternationally recognized lead<strong>in</strong>g regional full-service contract research<br />

organization (CRO), Novotech. <strong>The</strong> company has been deliver<strong>in</strong>g CRO services <strong>in</strong> the Asia-Pacific region for<br />

more than 23 years.<br />

Apart from the engag<strong>in</strong>g cover story, the issue encompasses the prom<strong>in</strong>ent leaders of the <strong>in</strong>dustry <strong>in</strong>clud<strong>in</strong>g<br />

David Health Solutions, a world leader <strong>in</strong> rehabilitation solutions for musculoskeletal problems; Sp<strong>in</strong>eMark<br />

Corporation, a premier global sp<strong>in</strong>e service company for the development of Sp<strong>in</strong>e Dest<strong>in</strong>ation Centers and<br />

Sp<strong>in</strong>e Research Organizations (SRO); Accutest Research Laboratories, a top-notch <strong>in</strong>dependent and<br />

<strong>in</strong>ternationally accredited India-based Contract Research Organization (CRO); an <strong>in</strong>terview by Sanomics, a<br />

fast-grow<strong>in</strong>g company contribut<strong>in</strong>g relentlessly to the future of healthcare with novel gene therapy solutions;<br />

Youshow AI tech Development; Pacific <strong>Healthcare</strong>; Paradigm Pharma; Teleme Technology; and Meditech<br />

Solution.<br />

This edition also <strong>in</strong>cludes few <strong>in</strong>terest<strong>in</strong>g articles by our <strong>in</strong>-house editors and <strong>in</strong>dustry expert.<br />

So, walk through the pages and enjoy a good read!


Editor-<strong>in</strong>-Chief Pooja M. Bansal<br />

Senior Editor Anish Miller<br />

Manag<strong>in</strong>g Editor Ashw<strong>in</strong>i S. Deshpande<br />

Executive Editor Aishwarya Nawandhar<br />

Contribut<strong>in</strong>g Editor Shambhavi Mhetre<br />

Visualiser David K<strong>in</strong>g<br />

Art & Design Head Amol Kamble<br />

Art & Design Assistant Poonam Mahajan<br />

Co-designer Paul Bel<strong>in</strong><br />

Art & Picture Editor Karan Gaikwad<br />

Bus<strong>in</strong>ess Development Manager Peter Coll<strong>in</strong>s<br />

Market<strong>in</strong>g Manager Marry D’Souza<br />

Bus<strong>in</strong>ess Development Executive Mark Williams<br />

Sales Executives Pooja, Amy, John<br />

Technical Head Jacob Smile<br />

Assistant Technical Head Pratiksha Patil<br />

Technical Consultants David, Robert<br />

Digital Market<strong>in</strong>g Manager Al<strong>in</strong>a Sege<br />

Assistant Digital Market<strong>in</strong>g Manager Prashant Chevale<br />

SME-SMO Executives Manoj, Gemson<br />

Research Analyst Eric Smith<br />

Circulation Manager Tanaji<br />

Insights Success Media Tech LLC<br />

555 Metro Place North, Suite <strong>10</strong>0,<br />

Dubl<strong>in</strong>, OH 43017, United States<br />

Phone - (614)-602-1754<br />

Email: <strong>in</strong>fo@<strong>in</strong>sightscare.com<br />

For Subscription: www.<strong>in</strong>sightscare.com<br />

We are also available on :<br />

sales@<strong>in</strong>sightscare.com<br />

June, 2019<br />

Corporate Ofces:<br />

Insights Success Media and Technology Pvt. Ltd.<br />

Ofce No. 22 & 5<strong>10</strong>, Ra<strong>in</strong>bow Plaza, Shivar Chowk,<br />

Pimple Saudagar, Pune, Maharashtra 41<strong>10</strong>17<br />

Phone - India: +91 74<strong>10</strong>079881/ 82/ 83/ 84/ 85<br />

Email: <strong>in</strong>fo@<strong>in</strong>sightscare.com<br />

For Subscription: www.<strong>in</strong>sightscare.com<br />

Follow us on : www.facebook.com/InsightsCare/<br />

https://twitter.com/Insightscare<br />

Copyright © 2019 Insights Success Media and Technology Pvt. Ltd., All rights reserved. <strong>The</strong> content and images used <strong>in</strong> this magaz<strong>in</strong>e should not be reproduced or<br />

transmitted <strong>in</strong> any form or by any means, electronic, mechanical, photocopy<strong>in</strong>g, record<strong>in</strong>g or otherwise, without prior permission from Insights success.<br />

Repr<strong>in</strong>t rights rema<strong>in</strong> solely with Insights Success Media and Technology Pvt. Ltd. Insights Care is powered by Insights Success Media and Technology Pvt. Ltd.


Dr. John Moller<br />

CEO


Cover Story<br />

NOVOTECH<br />

A Catalyst for Growth<br />

and a Better Tomorrow<br />

”<br />

A lead<strong>in</strong>g regional CRO <strong>in</strong> the Asia-Pacic region and the<br />

Biotech sector, offer<strong>in</strong>g full service cl<strong>in</strong>ical trial services<br />


<strong>The</strong> cost of research for new drugs has almost<br />

tripled over the last 25 years and new models are<br />

emerg<strong>in</strong>g to face these <strong>in</strong>creas<strong>in</strong>g expenses.<br />

Mult<strong>in</strong>ational pharmaceutical companies are deriv<strong>in</strong>g an<br />

even larger share of their revenues from biotech<br />

acquisitions or external discovery, and an <strong>in</strong>creas<strong>in</strong>g<br />

focus is put on cl<strong>in</strong>ical development operational<br />

improvements and optimization.<br />

Novotech is <strong>in</strong>ternationally recognized as the lead<strong>in</strong>g<br />

regional full-service contract research organization<br />

(CRO) <strong>in</strong> Asia-Pacific and is dedicated to support<strong>in</strong>g<br />

biotech companies <strong>in</strong> their drug development by tapp<strong>in</strong>g<br />

<strong>in</strong>to the benefits of the region. With a focus on cl<strong>in</strong>ical<br />

monitor<strong>in</strong>g, it has been <strong>in</strong>strumental <strong>in</strong> the success of<br />

hundreds of Phase I - IV cl<strong>in</strong>ical trials <strong>in</strong> the Asia Pacific<br />

region.<br />

Headquartered <strong>in</strong> Sydney, Novotech has been deliver<strong>in</strong>g<br />

CRO services <strong>in</strong> the region for more than 23 years. It has<br />

offices <strong>in</strong> twelve countries, <strong>in</strong>clud<strong>in</strong>g two customerfac<strong>in</strong>g<br />

offices <strong>in</strong> the US, and more than 550 staff to<br />

accommodate <strong>in</strong>creased demand from <strong>in</strong>ternational<br />

biotech companies for specialist cl<strong>in</strong>ical services.<br />

Strong Focus on Asia-Pacific with a Global Reach<br />

Novotech delivers cl<strong>in</strong>ical development services across<br />

all cl<strong>in</strong>ical trial phases and therapeutic areas. <strong>The</strong>se<br />

<strong>in</strong>clude feasibility assessments, ethics committee and<br />

regulatory submissions, data management, statistical<br />

analysis, medical monitor<strong>in</strong>g, safety services, central lab<br />

services, report write-up to ICH requirements, and<br />

project and vendor management. <strong>The</strong> company’s strong<br />

Asia Pacific presence allows them to run cl<strong>in</strong>ical trials <strong>in</strong><br />

all key regional markets. It also has worldwide reach<br />

through the company’s network of strategic partners.<br />

Full Service for Biotechnology <strong>Companies</strong><br />

Novotech is known as the lead<strong>in</strong>g regional CRO <strong>in</strong> the<br />

Asia-Pacific region and the biotech sector. <strong>The</strong> company<br />

and its employees have won numerous awards and<br />

recognitions <strong>in</strong> the CRO <strong>in</strong>dustry over the last several<br />

years and has been dedicated to deliver<strong>in</strong>g consistently<br />

high-quality service for its clients. In addition, the<br />

company ensures that the customer satisfaction is closely<br />

and objectively monitored across a range of KPIs<br />

throughout the lifespan of each project.<br />

Speak<strong>in</strong>g of what sets them apart <strong>in</strong> today’s highly<br />

competitive global world, Dr. John Moller, the CEO of<br />

Novotech, said, “Novotech is focused on deliver<strong>in</strong>g<br />

world-class cl<strong>in</strong>ical services <strong>in</strong> the Asia-Pacific region<br />

for the biotech sector. We offer the very latest <strong>in</strong> Oracle<br />

and Medidata technology, and all our projects are<br />

measured on quality of service and customer satisfaction<br />

throughout every stage of our engagement.”<br />

<strong>The</strong> customers of the company value its leadership as a<br />

regional CRO specialist, who can understand local<br />

cultures, customs, regulations, and have developed deep<br />

relationships with the key <strong>in</strong>vestigators <strong>in</strong> the region.<br />

Novotech follows a unique strategy for all its clients’<br />

projects. When discuss<strong>in</strong>g a new potential project with a<br />

client, the company br<strong>in</strong>gs <strong>in</strong> its senior cl<strong>in</strong>ical staff,<br />

country managers, and potentially <strong>in</strong>vestigators <strong>in</strong>to the<br />

discussions as early as possible. Through this, it ensures<br />

that the sponsor can ga<strong>in</strong> the confidence that their project<br />

will receive the attention they may not otherwise have<br />

with global CRO players.<br />

In addition to this, Novotech has a significant focus on<br />

appo<strong>in</strong>t<strong>in</strong>g and reta<strong>in</strong><strong>in</strong>g the best people and is strongly<br />

passionate about develop<strong>in</strong>g its employees. In fact, <strong>in</strong> the<br />

year of 2018, 30% of the company’s employees were<br />

promoted.<br />

Focused on Client Satisfaction<br />

Novotech has implemented a systematic mechanism of<br />

monitor<strong>in</strong>g customer and <strong>in</strong>vestigator satisfaction across<br />

a range of items. It has <strong>in</strong>vested <strong>in</strong> new technology and<br />

established clear processes to systematically reach out to<br />

its customers after key milestones for each project. <strong>The</strong><br />

company f<strong>in</strong>ds this <strong>in</strong>itiative very important as it nurtures<br />

relationships with its clients to address potential issues<br />

well <strong>in</strong> advance and ensures cont<strong>in</strong>uous improvement <strong>in</strong><br />

the services it provides. Validat<strong>in</strong>g the success of this<br />

approach is Novotech’s excellent levels of client<br />

satisfaction - mostly 8 and 9 out of <strong>10</strong> - and especially<br />

project communications which consistently scores above<br />

9 out of <strong>10</strong>.<br />

Follow<strong>in</strong>g are some feedback comments from from<br />

Novotech clients.<br />

“We’re delighted with the way our project was managed.<br />

<strong>The</strong> structure of hav<strong>in</strong>g the study team together with the<br />

governance team was effective. <strong>The</strong> team was very


”<br />

We ma<strong>in</strong>ta<strong>in</strong> and<br />

monitor the quality<br />

of service and client<br />

satisfaction at every<br />

step of our<br />

engagement<br />

”<br />

responsive, and issues were resolved with<strong>in</strong> expected<br />

timeframes.” - Senior Cl<strong>in</strong>ical Project Manager of a<br />

Swiss Biotech company<br />

Key Highlights of 2018<br />

Novotech’s acquisition of Australia specialist CNS last<br />

year was one of the major milestones <strong>in</strong> its journey. This<br />

acquisition has further strengthened Novotech’s presence<br />

<strong>in</strong> the region and has allowed the company to offer all<br />

clients a ‘BioDesk,’ capability that provides early stage<br />

product development advice <strong>in</strong>clud<strong>in</strong>g toxicology, CMC<br />

and FDA/EMA regulatory consult<strong>in</strong>g.<br />

Moreover, Asia-Pacific was the fastest grow<strong>in</strong>g region<br />

for biotech-sponsored trials aga<strong>in</strong> last year, with an<br />

<strong>in</strong>crease of about 35% compared with 2017. In the year<br />

2018, Novotech ma<strong>in</strong>ta<strong>in</strong>ed its focus on br<strong>in</strong>g<strong>in</strong>g <strong>in</strong> and<br />

reta<strong>in</strong><strong>in</strong>g the best people, nurtur<strong>in</strong>g relationships with<br />

clients, <strong>in</strong>vestigators and partners, and brand<br />

development <strong>in</strong>itiatives. <strong>The</strong> organization also made an<br />

important <strong>in</strong>vestment <strong>in</strong> relation to technology<br />

improvements with the next generation of Oracle’s Trial<br />

Management system.<br />

Novotech has further re<strong>in</strong>forced its position of lead<strong>in</strong>g<br />

CRO for the biotech sector <strong>in</strong> the Asia-Pacific region <strong>in</strong><br />

2018 with a very strong performance <strong>in</strong> key markets<br />

such as ANZ, Hong Kong, Thailand, Taiwan, and South<br />

Korea where Novotech estimates its market share has<br />

<strong>in</strong>creased to over 30% <strong>in</strong> key territories.<br />

Foundational Values<br />

Values are the roots of any company. <strong>The</strong> core values lay<br />

the foundation of an organization and helps def<strong>in</strong>e its<br />

vision and shape its culture. Novotech abides by the<br />

follow<strong>in</strong>g values:


Ÿ<br />

Ÿ<br />

Ÿ<br />

Ÿ<br />

Performance Passion – Accord<strong>in</strong>g to Novotech, an<br />

attitude of mak<strong>in</strong>g it happen drives a dedicated focus<br />

on engagement, quality, accountability, and<br />

performance results<br />

Open Engagement – Novotech’s style of work<strong>in</strong>g<br />

recognizes the value of everyone <strong>in</strong>volved<br />

Uncompromised Integrity – It follows the belief that<br />

one should never to hesitate to say or do the right<br />

th<strong>in</strong>g<br />

Unlock<strong>in</strong>g Talent - Novotech seeks and nurtures<br />

people with exceptional talent<br />

Novotech’s Take on Latest Developments<br />

Novotech believes that cl<strong>in</strong>ical data quality is considered<br />

the key priority for 2019. Accord<strong>in</strong>g to a recent survey<br />

conducted by J.P. Morgan amongst life sciences’<br />

<strong>in</strong>vestors this is especially true given the <strong>in</strong>creas<strong>in</strong>g<br />

complexity of trials and trial designs.<br />

Novotech has driven an <strong>in</strong>creas<strong>in</strong>g <strong>in</strong>vestment <strong>in</strong> upfront<br />

cl<strong>in</strong>ical development strategy, <strong>in</strong>clud<strong>in</strong>g the use of<br />

carefully designed protocols. <strong>The</strong>se <strong>in</strong>clude multi-arm,<br />

multi-stage designs with adaptive randomization.<br />

Accord<strong>in</strong>g to Novotech, an efficient approach to cl<strong>in</strong>ical<br />

trial design will have the greatest impact <strong>in</strong> conta<strong>in</strong><strong>in</strong>g<br />

the escalat<strong>in</strong>g cost of drug development. It also believes<br />

that the effectiveness of cl<strong>in</strong>ical trials also relies on the<br />

selection of the right <strong>in</strong>vestigators and excellence <strong>in</strong><br />

CRO study management. <strong>The</strong> company, therefore,<br />

<strong>in</strong>vests heavily <strong>in</strong> build<strong>in</strong>g formal partnerships with<br />

major hospitals and medical specialist sites through<br />

formal site partnership agreements, as well as site<br />

management services which facilitate rapid start-up<br />

activities and patient recruitment to meet the sponsor’s<br />

goals.<br />

Br<strong>in</strong>g<strong>in</strong>g <strong>in</strong> More for a Better Tomorrow<br />

With biotech companies <strong>in</strong>vest<strong>in</strong>g <strong>in</strong> more complex and<br />

global programs, Novotech sees that biotech sponsors<br />

are <strong>in</strong>creas<strong>in</strong>gly consider<strong>in</strong>g locations outside of the US<br />

for their trials, such as Eastern Europe and Asia-Pacific.<br />

<strong>The</strong> company’s cl<strong>in</strong>ical staff numbers have grown by<br />

more than 20% <strong>in</strong> Asia over the last quarter of 2018 and<br />

50% over the last twelve months. This growth <strong>in</strong> the<br />

number of staff members is fuelled by demand for a<br />

regional CRO with <strong>in</strong>ternational accreditation and<br />

reputation, comb<strong>in</strong>ed with local knowledge,<br />

partnerships, and expertise <strong>in</strong> the region. Furthermore,<br />

the company’s <strong>in</strong>itiative of <strong>in</strong>tegration of capabilities,<br />

such as BioDesk, will br<strong>in</strong>g tremendous support to<br />

biotech companies look<strong>in</strong>g for global regulatory<br />

services.


Interview with Insights Care<br />

Mr. Sy M<strong>in</strong>g Yiu<br />

CEO<br />

SANOMICS<br />

Improv<strong>in</strong>g <strong>Healthcare</strong> with Innovation and Compassion<br />

<strong>The</strong> healthcare <strong>in</strong>dustry is look<strong>in</strong>g for better answers to diagnose and treat various life-threaten<strong>in</strong>g diseases we hear of<br />

today. One of these diseases that the <strong>in</strong>dustry is try<strong>in</strong>g to combat s<strong>in</strong>ce long is cancer. Although there have been<br />

various advancements related to cancer treatment, no specific solution is reached yet. By far, the best possible<br />

solution comes from gene therapy. Apart from cancer treatment, gene therapy has showed a lot of potential to improve the<br />

treatment of number of deadly diseases.<br />

Sanomics is a fast-grow<strong>in</strong>g company, which is contribut<strong>in</strong>g relentlessly to the future of healthcare with novel gene therapy<br />

solutions. It is remarkably revolutioniz<strong>in</strong>g cancer treatments for the patients with safe and efficient liquid-based and tissuebased<br />

genomic tests. To know more about the story of this <strong>in</strong>genious company, we at Insightscare br<strong>in</strong>g to you an exclusive<br />

<strong>in</strong>terview with its CEO, Mr. Sy M<strong>in</strong>g Yiu, Stanley.<br />

1. Tell us <strong>in</strong> brief about Sanomics Limited.<br />

Established <strong>in</strong> Hong Kong Science and Technology Parks Corporation <strong>in</strong> 2015, Sanomics Limited is a Hong Kong based<br />

biotechnology start-up that specializes <strong>in</strong> liquid biopsy and tissue-based genomic diagnostics for cancer patients, so as to<br />

help doctors decide personalized cancer solutions for patients. S<strong>in</strong>ce 2015, Sanomics’ service covers 20 countries and<br />

regions and it has completed more than 7,000 patient cases over the world. Sanomics (Thailand) Limited was founded <strong>in</strong><br />

October 2018 <strong>in</strong> Bangkok, which is the first Hong Kong biotechnology start-up launched <strong>in</strong> Thailand.<br />

Focus<strong>in</strong>g on lung and women cancer, Sanomics’ comprehensive cancer genomic screen<strong>in</strong>g services covers both somatic<br />

mutation and germl<strong>in</strong>e mutations, adopt<strong>in</strong>g Droplet Digital Polymerase Cha<strong>in</strong> Reaction (ddPCR), Next Generation<br />

Sequenc<strong>in</strong>g (NGS) technology to complete Comprehensive Genomic Profil<strong>in</strong>g (CGP), and Real-time Polymerase Cha<strong>in</strong><br />

Reaction (Real-time PCR).<br />

16<br />

| June 2019 |


2. What were the motivat<strong>in</strong>g factors that led towards the <strong>in</strong>ception of the company?<br />

“Patient first” is absolutely the most motivat<strong>in</strong>g factor. An accurate genomic test result is critical for help<strong>in</strong>g doctors to<br />

design a personalized treatment for cancer patients. We strive to provide the genomic tests which are of higher quality,<br />

cheaper price, and quicker turnaround time to help cancer patients to save time and medical expenses.<br />

3. Which is your flagship product? Also, tell us how Sanomics stands tall and differentiates itself from others <strong>in</strong> this<br />

competitive world.<br />

®<br />

Requir<strong>in</strong>g only 20ml of blood and 2 work<strong>in</strong>g days of turnaround time, p-EGFR liquid biopsy test detects the EGFR gene<br />

mutation which causes lung cancer. Compar<strong>in</strong>g with traditional tissue biopsy which is an <strong>in</strong>vasive operation, costly, and<br />

® ®<br />

time consum<strong>in</strong>g, p-EGFR is non-<strong>in</strong>vasive, affordable, and quick. S<strong>in</strong>ce the launch of p-EGFR <strong>in</strong> August 2015 <strong>in</strong> Hong<br />

Kong, it has become the market leader <strong>in</strong> Hong Kong with<strong>in</strong> just 8 months.<br />

What makes Sanomics stand out is our dedication to execution. We always emphasis the <strong>in</strong>novation of Sanomics is <strong>in</strong><br />

execution. Rang<strong>in</strong>g from test request, specimen collection to release report, we try our best to keep the process as simple<br />

as possible, so that physicians’ precious time can be spent on treat<strong>in</strong>g patients <strong>in</strong>stead of deal<strong>in</strong>g with clumsy procedures.<br />

For example, we simplify the process of request<strong>in</strong>g Sanomics’ tests to 3 steps only and keep our form and test report <strong>in</strong> 1<br />

page to save time of physicians. Also, we launched Sanomics Portal mobile app for doctors to keep posted.<br />

4. What are all the products and services that Sanomics Limited provides?<br />

®<br />

<strong>The</strong> pEGFR test screens for the presence of Exon 19 deletions, Exon 21 L858R,<br />

Exon 20 T790M, C797S mutations <strong>in</strong> blood specimens us<strong>in</strong>g droplet digital PCR<br />

technology. This test is useful for assess<strong>in</strong>g and monitor<strong>in</strong>g whether TKI therapies<br />

would be effective mostly for lung cancer patients.<br />

<strong>The</strong> pBRAF V600ETM test screens for the presence of BRAF V600E mutation <strong>in</strong><br />

blood specimens us<strong>in</strong>g droplet digital PCR technology. <strong>The</strong> test targets lung, thyroid,<br />

colorectal, and melanoma and it is useful for assess<strong>in</strong>g whether the <strong>in</strong>dicated<br />

therapies would be useful. It is suggested that if the test results are positive,<br />

dabrafenib, and tramet<strong>in</strong>ib can be used as targeted therapy.<br />

Guardant360® identifies somatic mutations of 73 genes, proven to be cl<strong>in</strong>ically<br />

relevant, and reports on microsatellite <strong>in</strong>stability (MSI) status through the detection<br />

of circulat<strong>in</strong>g tumor DNA (ctDNA) <strong>in</strong> blood specimens us<strong>in</strong>g NGS technologies. <strong>The</strong><br />

test is suitable for patients with advanced solid tumors. <strong>The</strong> report would present<br />

targeted treatment options <strong>in</strong>clud<strong>in</strong>g approved therapies and therapies undergo<strong>in</strong>g<br />

late-stage cl<strong>in</strong>ical trials, as well as immunotherapy options. <strong>The</strong> test would be<br />

performed <strong>in</strong> the US.<br />

BRCA Zoom® identifies germl<strong>in</strong>e mutation of BRCA1 and BRCA2. <strong>The</strong> test is suitable<br />

for patients who have been diagnosed with breast, ovarian, prostate, and pancreatic<br />

cancer; people with family history of the above mentioned cancer and other cancer<br />

high-risk groups.<br />

Each person carries BRCA1 and BRCA2 genes. <strong>The</strong>se two genes are ma<strong>in</strong>ly<br />

responsible for repair<strong>in</strong>g damaged DNA and ma<strong>in</strong>ta<strong>in</strong><strong>in</strong>g stable cell growth.<br />

If a person carries a mutation of the BRCA gene, the risks of develop<strong>in</strong>g breast, ovarian,<br />

prostate cancer or pancreatic cancer <strong>in</strong> a lifetime also <strong>in</strong>creases. Also, the family<br />

members of that person would also have a possibility of carry<strong>in</strong>g the mutated BRCA<br />

genes.<br />

| June 2019 | 17


OncoSnap® is a pioneer<strong>in</strong>g tumor tissue profil<strong>in</strong>g test which screens for cl<strong>in</strong>ically<br />

relevant somatic mutations of 130 genes <strong>in</strong> solid tumor tissues by us<strong>in</strong>g NGS<br />

technologies, and offers FDA-approved therapies undergo<strong>in</strong>g cl<strong>in</strong>ical trials.<br />

Able to detect s<strong>in</strong>gle nucleotide variations (SNVs), <strong>in</strong>sertions and deletions (<strong>in</strong>dels),<br />

selected fusions and copy number alterations<br />

OncoSnap BRCATM is a pioneer<strong>in</strong>g NGS-based tumor tissue profil<strong>in</strong>g test which<br />

screens for somatic mutations of BRCA1 and BRCA2 genes <strong>in</strong> solid tumor tissues.<br />

This test is useful for assess<strong>in</strong>g patients who are diagnosed with breast cancer,<br />

ovarian cancer and prostate cancer on whether they could be benefited from selected<br />

PARP <strong>in</strong>hibitor treatments.<br />

OncoSnap NonetTM screens for 9 genes <strong>in</strong> tumor tissue samples, <strong>in</strong>tend<strong>in</strong>g to aid<br />

physicians to identify multi-genetic biomarkers for potential treatment options for<br />

primary diagnosed non-small-cell lung cancer patients.<br />

PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay us<strong>in</strong>g<br />

Monoclonal Mouse Anti-PD-L1, Clone 22C3 to detect PD-L1 prote<strong>in</strong> <strong>in</strong> FFPE tissue<br />

specimens us<strong>in</strong>g EnVision FLEX visualization system on Autosta<strong>in</strong>er L<strong>in</strong>k 48. It<br />

detects PD-L1 expression with a dynamic range of tumor-positive (TPS) 0-<strong>10</strong>0% and<br />

comb<strong>in</strong>ed positive score (CPS) 0-<strong>10</strong>+.<br />

Cancers <strong>in</strong>clude lung cancer, gastric cancer, urothelial cancer, cervical cancer, etc.<br />

EmbryoSafeTM screens all 24 chromosomes of IVF and ICSI embryos to detect<br />

pathogenic chromosome copy number changes, <strong>in</strong>clud<strong>in</strong>g aneuploidy, mosaicism,<br />

unbalanced translocations, and microduplications/microdeletions (> <strong>10</strong> Mb).<br />

5. With respect to your dist<strong>in</strong>ctive products and services, how have you helped br<strong>in</strong>g positive developments <strong>in</strong> the<br />

healthcare <strong>in</strong>dustry?<br />

Sanomics contributed to provide genomic tests to help doctors decide personalized cancer solutions for patients. We keep<br />

provid<strong>in</strong>g solutions to tackle with the pa<strong>in</strong> po<strong>in</strong>ts <strong>in</strong> current cancer management process. For example, Sanomics is the<br />

first local private company <strong>in</strong> Hong Kong to adopt liquid biopsy, a non-<strong>in</strong>vasive cancer screen<strong>in</strong>g technology that spares<br />

patients from the pa<strong>in</strong>ful tissue biopsy, a traditional procedure of collect<strong>in</strong>g tissue samples from tumors. Another example<br />

is that tissue samples often run outs before answer<strong>in</strong>g all the cl<strong>in</strong>ical questions that guide treatment selection, therefore,<br />

TM<br />

by launch<strong>in</strong>g OncoSnap Nonet , this test can screen for 9 genes <strong>in</strong> tumor tissue samples to make best use of tissue.<br />

6. Are there any social activities that your company organizes to uplift healthcare space?<br />

To raise the public awareness of adopt<strong>in</strong>g genomic test <strong>in</strong> cancer management, Sanomics organizes workshops and<br />

sem<strong>in</strong>ars for healthcare professionals and general public. We also co-operate with our strategic partners, such as<br />

18<br />

| June 2019 |


AstraZeneca and Bio-Rad to organize large scale symposium, to discuss about the latest development of genomic<br />

diagnostics and provide a platform for <strong>in</strong>tellectual exchange <strong>in</strong> the healthcare <strong>in</strong>dustry.<br />

7. Tell us some <strong>in</strong>terest<strong>in</strong>g th<strong>in</strong>gs about your leader (CEO, CFO, COO or any other personality which you want to<br />

highlight <strong>in</strong> this issue).<br />

“Keep mov<strong>in</strong>g, keep th<strong>in</strong>k<strong>in</strong>g and keep solv<strong>in</strong>g”, this is the common value that we share <strong>in</strong> Sanomics.<br />

8. Mention the notable awards and accreditations Sanomics has received so far.<br />

So far, Sanomics has won 19 awards. Some highlighted awards <strong>in</strong>clude:<br />

2018 <strong>The</strong> Top 50 Innovative Biotechnology Enterprises <strong>in</strong> Guangdoug-Hong Kong-Macau Greater Bay Area by<br />

ZDVC Research Institute, KPMG & Guangdoug Medical Valley<br />

Innovative Bus<strong>in</strong>ess Gold Award 2018 by <strong>The</strong> Hong Kong and Shanghai Bank<strong>in</strong>g Corporation Limited and Hong<br />

Kong Economic Times<br />

Car<strong>in</strong>g Company Award by <strong>The</strong> Hong Kong Council of Social Service<br />

9. Can you share with us your upcom<strong>in</strong>g projects?<br />

Big data will be our next step. Big Data is everywhere <strong>in</strong> our daily life, actually DNA big data can also be digitalized to<br />

assist scientists and doctors to analyze and make advances <strong>in</strong> cancer treatment. Currently, there is no exist<strong>in</strong>g DNA<br />

database of Asian cancer patients. To address the need for build<strong>in</strong>g Asian cancer patients’ big data, we <strong>in</strong>itiate to establish<br />

a DNA Big Data Centre <strong>in</strong> Hetao district at Lok Ma Chau. By do<strong>in</strong>g so, we aim to attract more genetic related start-ups to<br />

set up their offices <strong>in</strong> Great Bay Area, so as to create an ecosystem of biotechnology companies <strong>in</strong> Great Bay Area.<br />

<strong>The</strong> <strong>in</strong>itial design of this DNA big database is by subscription base. <strong>The</strong> meta data of the database will be open for public<br />

access. However, to get full access, users must register and pay certa<strong>in</strong> amount of subscription fee, as well as unveil<strong>in</strong>g<br />

their data model to susta<strong>in</strong> the platform. <strong>The</strong> three ma<strong>in</strong> roles of the owner of this DNA Big Data Centre are - first, to<br />

provide basic legal support and protection to the DNA data supply<strong>in</strong>g and demand<strong>in</strong>g sides; second, to set up a rat<strong>in</strong>g<br />

scheme and payment scheme for DNA data transaction; and thirdly, to be the DNA big data manager. <strong>The</strong> idea of this<br />

Asian DNA big data base is like a comb<strong>in</strong>ation of Asian DNA eBay and DNA cloud.<br />

We believe that more valuable studies and commercialized applications of DNA data will be generated once this Asian<br />

Big Data shar<strong>in</strong>g platform has been launched. We foresee that ultimately this will enhance the overall life quality and<br />

improve the cancer solution for<br />

Asian.<br />

Fig.: Important Milestones <strong>in</strong> the Journey of Sanomics<br />

| June 2019 | 19


Tania Mart<strong>in</strong>-Mercado<br />

Chief Technology Ofcer<br />

ABOUT THE AUTHOR<br />

Tania Mart<strong>in</strong>-Mercado, PhD, is the Chief Technology Ofcer of YGEIA,<br />

a digital healthcare company focused on home healthcare and chronic disease<br />

management. She holds various degrees <strong>in</strong> IT, healthcare, as well as biotechnology and<br />

is seasoned with a lot of experience at various prestigious posts throughout the years. Be<strong>in</strong>g a<br />

curious soul and always been fasc<strong>in</strong>ated with technology, Tania has been a part of various<br />

healthcare <strong>in</strong>novations.<br />

22<br />

| June 2019 |


Industry Insight<br />

WHAT<br />

DIGITAL STARTUPS<br />

NEED TO SUCCEED IN THE<br />

HEALTHCARE SPACE<br />

e hear a lot of buzz <strong>in</strong> the <strong>in</strong>dustry and <strong>in</strong> the<br />

Wmarketplace about the latest <strong>in</strong> digital<br />

healthcare. From artificial <strong>in</strong>telligence, mach<strong>in</strong>e<br />

learn<strong>in</strong>g, remote patient monitor<strong>in</strong>g and wearable<br />

technology to home monitor<strong>in</strong>g and data, data, data –<br />

digital healthcare has morphed <strong>in</strong>to one of the most<br />

transformative healthcare trends.<br />

While this is one of the most excit<strong>in</strong>g times to be <strong>in</strong> the<br />

digital healthcare market, startups focused on this space<br />

need to make sure their product and service have three-fold<br />

impact: Improved patient outcomes, reduced cost of<br />

delivery, and quality of care. Cost, quality and patient<br />

experience often go unnoticed or ignored <strong>in</strong> favor of<br />

technical functionality. <strong>The</strong> latest and greatest digital<br />

healthcare technology will fail if the patients don’t<br />

understand how to use it, providers can’t implement it <strong>in</strong>to<br />

their workflow, and payors won’t reimburse for its use.<br />

By start<strong>in</strong>g with a patient-centered focus, digital startups<br />

will f<strong>in</strong>d they may need to slow down and get a better<br />

understand<strong>in</strong>g of the healthcare <strong>in</strong>dustry, which operates<br />

differently than the tech world. <strong>The</strong>re are more stakeholders<br />

<strong>in</strong> healthcare that need consideration: doctors, patients,<br />

<strong>in</strong>surers, regulators; each of these stakeholders holds a<br />

unique perspective on the technology be<strong>in</strong>g adopted.<br />

<strong>Healthcare</strong> is complex because patients are complex. As<br />

digital startups focus on one area, such as a particular<br />

disease, they may stumble onto the multiple factors that<br />

contribute to that disease, what <strong>in</strong>surers do and don’t cover<br />

related to that disease and its symptoms, and more variables<br />

that directly or <strong>in</strong>directly affect their product or service.<br />

<strong>The</strong> development of a product or service requires research<br />

<strong>in</strong>to cl<strong>in</strong>ical practice, medical study, patient and doctor<br />

<strong>in</strong>terviews, and several focus groups. Digital healthcare<br />

startups need to have patience – someth<strong>in</strong>g that is<br />

unattractive to some <strong>in</strong>vestors, caus<strong>in</strong>g digital healthcare<br />

startups to rush <strong>in</strong>to product development too quickly.<br />

Instead, <strong>in</strong>volv<strong>in</strong>g key stakeholders early <strong>in</strong> the<br />

development process and fully understand<strong>in</strong>g the concerns<br />

and perspective will allow these startups to impact the<br />

healthcare space where it matters most – patient care.<br />

<strong>The</strong> Medical Futurist published a fantastic article earlier<br />

this year that highlights why healthcare startups fail.<br />

Forgett<strong>in</strong>g about the patient, not <strong>in</strong>clud<strong>in</strong>g the provider,<br />

difficulty creat<strong>in</strong>g cl<strong>in</strong>ical value and overclaim<strong>in</strong>g what the<br />

technology can do area just a few of areas discussed <strong>in</strong> this<br />

article.<br />

Another area often overlooked by digital healthcare startups<br />

is the need to <strong>in</strong>tegrate. <strong>Healthcare</strong> data is massive, and<br />

there is no “central repository” to draw from. By<br />

understand<strong>in</strong>g and embrac<strong>in</strong>g the need for shared services,<br />

<strong>in</strong>tegration with other startups or providers <strong>in</strong> the healthcare<br />

<strong>in</strong>dustry can foster <strong>in</strong>novation and better meet patient need<br />

or demand. Instead startups may focus on siloed solutions<br />

that make it difficult for providers to implement <strong>in</strong>to their<br />

practice, thus not offer<strong>in</strong>g value to the patient. By<br />

understand<strong>in</strong>g how patient data is viewed from a provider<br />

and payor perspective, digital healthcare startups will f<strong>in</strong>d<br />

out how their product or service will be most useful.<br />

This is such an excit<strong>in</strong>g time to be <strong>in</strong> the healthcare space.<br />

<strong>The</strong> satisfaction of mak<strong>in</strong>g a positive impact <strong>in</strong><br />

communities by improv<strong>in</strong>g patient care is why many<br />

startups dive <strong>in</strong>to the healthcare space. By tak<strong>in</strong>g a few of<br />

these po<strong>in</strong>ts <strong>in</strong>to consideration, digital healthcare startups<br />

will f<strong>in</strong>d their endeavors bear<strong>in</strong>g fruit.<br />

| June 2019 | 23


‘‘<br />

‘‘<br />

eadquarter <strong>in</strong> Hels<strong>in</strong>ki, F<strong>in</strong>land; David Health Solutions Ltd.<br />

His a rehabilitation solutions provider for musculoskeletal<br />

problems. Established <strong>in</strong> the year 1981 by Arno Parvia<strong>in</strong>en,<br />

the CEO, the company has its operations on a global platform. <strong>The</strong><br />

company is transform<strong>in</strong>g sp<strong>in</strong>e and orthopedic care with a data-driven,<br />

device-based exercise therapy solution that is directly <strong>in</strong> consensus with<br />

the latest guidel<strong>in</strong>es. It promotes exercise and cognitive support as the<br />

first l<strong>in</strong>e treatment for most chronic musculoskeletal problems.<br />

Exercise comb<strong>in</strong>ed with the body’s ability to regenerate is a powerful<br />

tool. Unfortunately, it is underutilized <strong>in</strong> healthcare. However, times are<br />

chang<strong>in</strong>g. What DHS found out over 30 years ago is becom<strong>in</strong>g the<br />

norm now. Indeed, its solution used to be the last remedy <strong>in</strong> the<br />

toolbox; now, it is the first. Decades ago, Arno was conv<strong>in</strong>ced that the<br />

best way to treat musculoskeletal pa<strong>in</strong> was targeted and controlled<br />

exercise therapy us<strong>in</strong>g specially designed devices. Hav<strong>in</strong>g started small,<br />

David Health Solutions has now set up more than 350 centers around<br />

the world us<strong>in</strong>g its <strong>in</strong>telligent solutions for sp<strong>in</strong>e and orthopedic care.<br />

<strong>The</strong> Journey of Innovation & Intelligence<br />

Several years were spent on <strong>in</strong>tense research and development <strong>in</strong><br />

build<strong>in</strong>g biomechanically optimal tra<strong>in</strong><strong>in</strong>g devices for each jo<strong>in</strong>t. David<br />

Health Solutions quickly found out that with this approach it was<br />

possible to start movement and tra<strong>in</strong><strong>in</strong>g, even for the patients suffer<strong>in</strong>g<br />

from severe pa<strong>in</strong>. <strong>The</strong> key was to design devices that were gentle for<br />

the jo<strong>in</strong>ts, but demand<strong>in</strong>g for the muscles. <strong>The</strong> company visualizes<br />

becom<strong>in</strong>g the torchbearer <strong>in</strong> one of the biggest changes <strong>in</strong> healthcare,<br />

cover<strong>in</strong>g the most costly and debilitat<strong>in</strong>g healthcare problem.<br />

“In anyth<strong>in</strong>g we do, the well-be<strong>in</strong>g of the patient is always the most<br />

24<br />

| June 2019 |


important factor. No technology alone can solve these<br />

problems unless there are unified m<strong>in</strong>ds at all levels to<br />

br<strong>in</strong>g the benefits to the patient,” asserts Arno. <strong>The</strong><br />

company is strictly a ‘school medic<strong>in</strong>e’ company,<br />

mean<strong>in</strong>g that it makes no unsubstantiated claims and<br />

bases its philosophy on data and science. <strong>The</strong>refore, to<br />

keep up with technology, it is now develop<strong>in</strong>g an AI<br />

system that can learn from the hundreds of thousands of<br />

patient cases to provide better and more <strong>in</strong>dividualized<br />

care for each patient.<br />

David Health Solutions works on the core value of<br />

‘patient wellbe<strong>in</strong>g’, this is also the reason it is<br />

transform<strong>in</strong>g itself from a device company to a service<br />

company. “This is the only way we can ensure the best<br />

quality and operational efficiency. We have centers<br />

under the “Nordic Health” brand, either owned by us or<br />

under our management <strong>in</strong> F<strong>in</strong>land, Netherlands, Saudi<br />

Arabia, and now com<strong>in</strong>g to USA. Our first Nordic Health<br />

Sp<strong>in</strong>e and Ortho Center will open <strong>in</strong> Tulsa, Oklahoma, <strong>in</strong><br />

partnership with neurosurgeons. <strong>The</strong> next ones will open<br />

<strong>in</strong> California and New Jersey,” says Arno. <strong>The</strong>re is a<br />

great need for <strong>in</strong>tegrated services provid<strong>in</strong>g the whole<br />

cont<strong>in</strong>uum of care, believes DHS.<br />

curves, guarantee<strong>in</strong>g safe and pa<strong>in</strong>-free tra<strong>in</strong><strong>in</strong>g<br />

experience. Its cloud based, state-of-the-art IT system<br />

guides and motivates the patient and simultaneously<br />

collects all relevant data automatically for easy<br />

report<strong>in</strong>g.<br />

Every device is also a test<strong>in</strong>g device for strength and<br />

mobility. Based on these test results, the software will<br />

automatically provide <strong>in</strong>dividualized tra<strong>in</strong><strong>in</strong>g weights<br />

and movement ranges. All parameters of the exercise are<br />

digitally controlled this way. Nordic Health cl<strong>in</strong>ic, which<br />

is equipped with the full system, is frequently visited by<br />

the staff of the cl<strong>in</strong>ic for exercise and preventative care.<br />

“It is great to see everyone, from our COO to our<br />

Market<strong>in</strong>g Associates, so enthusiastic to utilize the<br />

technology for both rehabilitation and preventive care,”<br />

he says.<br />

<strong>The</strong> company’s medical rehabilitation system is unique<br />

because it is the only fully equipped solution <strong>in</strong> the<br />

market. <strong>The</strong> DAVID product portfolio <strong>in</strong>cludes<br />

<strong>in</strong>telligent devices that specifically target the sp<strong>in</strong>e, hip<br />

& knee, and shoulder jo<strong>in</strong>ts. This is great news for<br />

rehabilitation cl<strong>in</strong>ics because the practice can offer<br />

Dist<strong>in</strong>ctive Services and Solutions<br />

<strong>The</strong> David Exercise <strong>The</strong>rapy Solution utilizes specially<br />

designed devices with jo<strong>in</strong>t-specific isolation and load<strong>in</strong>g<br />

| June 2019 | 25


patients care for a variety of musculoskeletal problems<br />

with a turn-key solution that has been validated <strong>in</strong> a<br />

number of studies and <strong>in</strong> use <strong>in</strong> hundreds of centers.<br />

Dist<strong>in</strong>guish<strong>in</strong>g Itself from Others<br />

Typical services <strong>in</strong> this area are run by therapists on a<br />

one-to-one basis, us<strong>in</strong>g poor and outdated tools. This is a<br />

very consum<strong>in</strong>g work for the therapists and the work is<br />

typically quite random. <strong>The</strong>re are no standardized and<br />

structured programs and due to high costs, most<br />

programs are cut short before the patient is well.<br />

DAVID’s <strong>in</strong>novative solution uses advanced tra<strong>in</strong><strong>in</strong>g<br />

technology and cloud-based software for guidance,<br />

control, and data-gather<strong>in</strong>g. This has dramatically<br />

changed the role of the therapists from manual workers<br />

to that of a coach, expert, and motivator. After a few<br />

sessions with the therapists, a patient learns to use the<br />

system <strong>in</strong>dependently and is empowered to take care of<br />

his/her own health. This frees the therapists to<br />

concentrate on the more difficult cases, while the<br />

technology guides the other patients through the<br />

program. “Up to six patients can be treated by one<br />

therapist,” says Arno.<br />

This has also opened a completely new market for<br />

medical centers, the on-go<strong>in</strong>g prevention care with a<br />

membership model. Most of the patients that went<br />

through the program are will<strong>in</strong>g to cont<strong>in</strong>ue once a week<br />

<strong>in</strong> the ma<strong>in</strong>tenance program. This requires very little<br />

personnel resources and provides steady <strong>in</strong>come stream<br />

for the cl<strong>in</strong>ic.<br />

Awards and Appreciations<br />

<strong>The</strong> company and Parvia<strong>in</strong>en have been awarded tens of<br />

different patents <strong>in</strong> connection to technical solutions and<br />

methods. <strong>The</strong> company’s production has an ISO 13485<br />

certificate which is GMP <strong>in</strong> Europe, cover<strong>in</strong>g production<br />

of medical devices. All the devices are also separately<br />

medically certified. <strong>The</strong> praise it receives form its<br />

26<br />

| June 2019 |


customers speaks leaps and bounds of the company’s excellent<br />

service.<br />

“We at St. Lucas <strong>in</strong> Bruges, Belgium, adopted the use of device-based<br />

back treatment already <strong>in</strong> 1998. Due to the evidence of its efficacy, a<br />

national <strong>in</strong>surance code was issued for this method. In December of<br />

2015, we moved to a new phase <strong>in</strong> our operation when we changed to<br />

a fully <strong>in</strong>tegrated DAVID Solution with automatic adjustments,<br />

patient guidance, and track<strong>in</strong>g of all critical variables. Our<br />

experience is that patients are more motivated, results seem to be<br />

better, and <strong>in</strong>tegration to the hospital’s electronic patient record<br />

system saves a lot of adm<strong>in</strong>istrational work.”−Dr. Marc Soenen, AZ<br />

S<strong>in</strong>t-Lucas Hospital<br />

“Hav<strong>in</strong>g been a neurosurgeon for over thirty years, I have always<br />

ma<strong>in</strong>ta<strong>in</strong>ed the desire to explore conservative, non-operative options<br />

for my patients. In 2015, we became acqua<strong>in</strong>ted with the DAVID<br />

Sp<strong>in</strong>e Concept. We have been so impressed with the DAVID Solution<br />

that we are on our third set of DAVID Sp<strong>in</strong>e equipment and have now<br />

<strong>in</strong>tegrated DAVID’s hip and shoulder therapy as well. It is reward<strong>in</strong>g<br />

to see that active rehabilitation can dramatically change people’s<br />

lives for the better and help them avoid surgery.” −Luke Knox M.D.<br />

F.A.C.S, Northwest Arkansas Neurosurgery Cl<strong>in</strong>ic<br />

Bright Future of DAVID<br />

<strong>The</strong> fact that device-based exercise therapy is go<strong>in</strong>g to ga<strong>in</strong> ground <strong>in</strong><br />

the medical world is already clear. National level <strong>in</strong>surance<br />

reimbursements and contracts with health m<strong>in</strong>istries <strong>in</strong> different<br />

countries are a proof of that, believes Arno. “When people become<br />

more familiar with these ideas and have a chance to personally try <strong>in</strong><br />

practice how the system works, attitudes will change,” he says. <strong>The</strong><br />

company strives to improve its operations and offer<strong>in</strong>gs to cont<strong>in</strong>ue to<br />

provide the world’s most comprehensive solution for musculoskeletal<br />

rehabilitation.<br />

<strong>The</strong> next major jump forward will be when David Health Solutions<br />

will put its AI eng<strong>in</strong>e <strong>in</strong> cl<strong>in</strong>ical use. This system will provide the<br />

most accurate and <strong>in</strong>dividualized care of any system available. It will<br />

consider all background factors of the patient, like diagnosis, pa<strong>in</strong><br />

level, education, psychological profile, test results, and so on. It will<br />

well understand that musculoskeletal problems are complex, and not<br />

only physical, and therefore it is critical to <strong>in</strong>corporate all success and<br />

failure factors <strong>in</strong> the program.<br />

To know more, visit www.davidhealth.com<br />

Mr. Arno Parvia<strong>in</strong>en<br />

CEO & Founder<br />

“Life is a Marathon”<br />

Arno Parvia<strong>in</strong>en knows the power of<br />

exercise firsthand. A er mul ple<br />

<strong>in</strong>juries <strong>in</strong> water ski<strong>in</strong>g, cycl<strong>in</strong>g, and<br />

tennis, he could have been disabled<br />

with any of those <strong>in</strong>cidences. But he<br />

was fortunate to know the possibili es<br />

device-based tra<strong>in</strong><strong>in</strong>g can offer. <strong>The</strong><br />

most serious <strong>in</strong>jury caused a caudaequ<strong>in</strong>a<br />

with total nerve block and<br />

paralyzed his calves. It took him five<br />

years of persistent tra<strong>in</strong><strong>in</strong>g and runn<strong>in</strong>g<br />

before he was able to run same<br />

distances and at same speeds as before<br />

the accident. His experience is well<br />

documented <strong>in</strong> his blog: “Life is a<br />

marathon”.<br />

Parvia<strong>in</strong>en has a degree <strong>in</strong> economics,<br />

but his knowledge <strong>in</strong> how to build<br />

biomechanically correct devices is very<br />

rare <strong>in</strong> the <strong>in</strong>dustry. He started his<br />

<strong>in</strong>terest a er travell<strong>in</strong>g <strong>in</strong> the US at the<br />

age of seventeen and got acqua<strong>in</strong>ted<br />

with devices <strong>in</strong> the market there. He<br />

built his own set of devices at the age<br />

of eighteen and from there on his<br />

passion has been to develop<br />

technologies that can help pa ents<br />

suffer<strong>in</strong>g <strong>in</strong> back and jo<strong>in</strong>t pa<strong>in</strong>.<br />

| June 2019 | 27


In-house Op<strong>in</strong>ion<br />

Social Media<br />

Market<strong>in</strong>g<br />

A Necessary Trend to Pick for <strong>Healthcare</strong> Professionals<br />

Today, we don’t know if we are conquer<strong>in</strong>g the digital world or the digital world is<br />

conquer<strong>in</strong>g us. Liv<strong>in</strong>g <strong>in</strong> an era like this, we need to ensure we are abreast with all the<br />

trends and developments that directly affect us. One trend that has moved all the<br />

<strong>in</strong>dustries and all parts of the world is the extensive use of social media. <strong>The</strong> millennial<br />

generation has embraced various social platforms with open arms and it is now a major part of<br />

their lives. On the top of this generation is the next, generation Z. Generation Z, also known as<br />

the iGeneration, is immersed <strong>in</strong> technology. <strong>The</strong>y spend most of their time on social media.<br />

It has, therefore, become very important for all types of bus<strong>in</strong>esses <strong>in</strong> all the sectors to leverage<br />

the technique of social media market<strong>in</strong>g to attract the millennials and genzers. This will not only<br />

<strong>in</strong>crease the sales but help you build a cha<strong>in</strong> of loyal customers.<br />

28<br />

| June 2019 |


| June 2019 | 29


<strong>Healthcare</strong> <strong>in</strong>dustry is also affected by this trend, but it lags<br />

beh<strong>in</strong>d <strong>in</strong> exploit<strong>in</strong>g it to the fullest. Let’s understand what<br />

benefits it br<strong>in</strong>gs to you.<br />

<strong>The</strong> idea of search<strong>in</strong>g and follow<strong>in</strong>g a doctor on some<br />

social platform would seem absurd if you thought about it a<br />

few years back. But, time has changed and so has the trend.<br />

When it comes to health, although people won’t shop<br />

around, they will still look for the best. Advertis<strong>in</strong>g<br />

everyth<strong>in</strong>g that a provider has to offer on a platform<br />

reach<strong>in</strong>g anyone and everyone is a great idea to mark<br />

him/her <strong>in</strong> the m<strong>in</strong>ds of people.<br />

Additionally, users, all around the globe, surf their social<br />

media feeds number of times a day. If one makes sure to<br />

update their account regularly, users are likely to come<br />

across their post number of times. This leaves an impact on<br />

the users. Where else can one make their presence felt so<br />

frequently?<br />

It also allows a company to connect with their patients <strong>in</strong><br />

real-time. And this can be done from anywhere and<br />

everywhere!<br />

With social media, you can ensure customer-centricity.<br />

Putt<strong>in</strong>g up health tips and stay<strong>in</strong>g <strong>in</strong> touch with the patients<br />

through social platforms are some ways to do this.<br />

Moreover, healthcare providers can put up about the<br />

practices, services, and products that they provide and the<br />

stories of how they have helped others for better. This will<br />

help them build a sense of trust <strong>in</strong> the clients as well as the<br />

audience visit<strong>in</strong>g their account.<br />

Other than this, social media market<strong>in</strong>g comes with a lot<br />

more advantages. To stand out and make it fun, here are a<br />

few ways that will help.<br />

Educational Posts<br />

A healthcare brand can educate their clients or patients<br />

through their social media feed. This can <strong>in</strong>clude post<strong>in</strong>g<br />

health tips, a video of successful surgery carried by a<br />

hospital, awareness and precautions for particular disease,<br />

short description of a new device or technology, and many<br />

more. Be<strong>in</strong>g connected with the brand, the patients will<br />

look out for such tips and probably implement them as well.<br />

Not only will it help the brand <strong>in</strong> build<strong>in</strong>g better<br />

relationship with its clients, but also help improve the<br />

patients’ lifestyle.<br />

30<br />

Start a Campaign, Use Hash tags<br />

It is a very good idea for a healthcare company to start its<br />

own campaign on social media. <strong>The</strong> campaign can be about<br />

anyth<strong>in</strong>g from awareness about a disease to encourag<strong>in</strong>g<br />

audience to share their success stories to start<strong>in</strong>g a social<br />

<strong>in</strong>itiative and call<strong>in</strong>g out audience to jo<strong>in</strong> <strong>in</strong>. Us<strong>in</strong>g hash<br />

tags to promote such campaigns br<strong>in</strong>gs a lot of benefits. Say<br />

for example, a company starts a campaign for the patients<br />

of aids, call<strong>in</strong>g out people to share the success stories of<br />

themselves or their loved ones <strong>in</strong> conquer<strong>in</strong>g aids. Hash tag<br />

like #companynameforaids can be used by everyone jo<strong>in</strong><strong>in</strong>g<br />

<strong>in</strong> the campaign. This helps improve the company’s<br />

brand<strong>in</strong>g alongside a good cause.<br />

Interactive Communication<br />

Clients/patients do not usually <strong>in</strong>dulge <strong>in</strong> the <strong>in</strong>teractive<br />

communication with the healthcare providers. On a social<br />

platform, this can be <strong>in</strong>itiated. This will help the patients<br />

feel more close to the company and hence, build a long,<br />

trustful relationship.<br />

Leverage Infographics<br />

Infographics can help one provide highly <strong>in</strong>formative<br />

content <strong>in</strong> very short time. Without tak<strong>in</strong>g up a lot of the<br />

audience’s time, a company can portray its strengths with<br />

the help of <strong>in</strong>fographics. A step further is <strong>in</strong>fographic<br />

videos. <strong>The</strong>y say a lot of th<strong>in</strong>gs <strong>in</strong> matter of seconds. Also,<br />

the comb<strong>in</strong>ation of an audio, video, content, and colors is<br />

easier to remember and leaves a high impact on the<br />

viewers.<br />

<strong>The</strong>se are just some of the ways to leverage social media<br />

for market<strong>in</strong>g by healthcare brands. <strong>The</strong> scope for ideas is<br />

wide, as when it comes to creativity, the sky is the limit. It<br />

is the need of the hour to walk with the trends of the world<br />

and use them for your benefit. Social media market<strong>in</strong>g<br />

br<strong>in</strong>gs <strong>in</strong> a vast opportunity for healthcare companies to<br />

brand and advertise their strengths and connect to the<br />

clients better.<br />

- Aishwarya Nawandhar, Editor<br />

| June 2019 |


Accutest Research<br />

Laboratories<br />

<strong>The</strong> Preferred CRO Partner for<br />

<strong>Healthcare</strong> <strong>Companies</strong><br />

he healthcare <strong>in</strong>dustry <strong>in</strong> India<br />

Thas caught pace and is mov<strong>in</strong>g<br />

ahead with cont<strong>in</strong>uous<br />

developments. CROs are play<strong>in</strong>g a<br />

major role <strong>in</strong> this and have witnessed a<br />

positive growth <strong>in</strong> the past few years.<br />

Through outsourced R&D services to<br />

the pharma, cl<strong>in</strong>ical device, and<br />

biotechnology companies, CROs br<strong>in</strong>g<br />

<strong>in</strong> the promise of further developments<br />

<strong>in</strong> the healthcare space. From cl<strong>in</strong>ical<br />

research to product development, these<br />

companies provide the processes and<br />

services on contract basis. One of the<br />

lead<strong>in</strong>g companies contribut<strong>in</strong>g to the<br />

future of Indian healthcare <strong>in</strong>dustry<br />

through its comprehensive services is<br />

Accutest Research Laboratories (I)<br />

Pvt. Ltd.<br />

Headquartered <strong>in</strong> Navi Mumbai,<br />

Accutest is a top-notch <strong>in</strong>dependent<br />

and <strong>in</strong>ternationally accredited Indiabased<br />

Contract Research Organization<br />

(CRO). Incepted <strong>in</strong> 1998, it offers best<strong>in</strong>-class<br />

services along the whole drug<br />

development process to<br />

pharmaceutical, generics, and<br />

biotechnology companies. <strong>The</strong><br />

company operates out of three facilities<br />

viz. Navi Mumbai, Ahmedabad, and<br />

Baroda. Accutest has emerged to be the<br />

undisputed leader <strong>in</strong> BABE segment<br />

for over two decades now.<br />

Dr. Satish Sawant<br />

Founder & CEO<br />

<strong>The</strong> Sculptor of Accutest<br />

Dr. Satish Sawant, the Founder and<br />

CEO of Accutest, is a very down to<br />

earth technocrat and a cricket<br />

enthusiast. He has completed his<br />

doctorate <strong>in</strong> analytical chemistry. He<br />

has spearheaded and shaped the<br />

<strong>in</strong>credible journey of Accutest as one<br />

of lead<strong>in</strong>g CROs <strong>in</strong> the <strong>in</strong>dustry<br />

through his sheer grit, farsighted<br />

bus<strong>in</strong>ess strategies, and zeal to<br />

consistently add value to research<br />

<strong>in</strong>dustry. His bus<strong>in</strong>ess acumen has<br />

rightly led him to exploit the huge<br />

demand <strong>in</strong> the market for BABE<br />

studies conduction as a mandatory<br />

regulatory requirement for the generic<br />

pharma manufacturers.<br />

Dr. Sawant has been <strong>in</strong>strumental <strong>in</strong><br />

manifold growth of Accutest by sett<strong>in</strong>g<br />

up a friendly and <strong>in</strong>clusive work<br />

culture, which does not compromise on<br />

quality while serv<strong>in</strong>g the clients with<br />

utmost <strong>in</strong>tegrity and efficiency.<br />

Journey<strong>in</strong>g to the Top<br />

<strong>The</strong> idea of Accutest Research<br />

Laboratories was on the m<strong>in</strong>d of Dr.<br />

Sawant s<strong>in</strong>ce he completed his Ph. D <strong>in</strong><br />

Pharmaceutical Sciences. After serv<strong>in</strong>g<br />

Indian pharma <strong>in</strong>dustry for about 15<br />

years <strong>in</strong> the areas of drug research<br />

related to pharma test<strong>in</strong>g us<strong>in</strong>g various<br />

modern chromatographic techniques,<br />

Dr Sawant set on a path to turn his<br />

long cherished dream <strong>in</strong>to reality. In<br />

1998, Accutest entered the <strong>in</strong>dustry as<br />

a small startup. Initially tak<strong>in</strong>g up<br />

small projects, the company gradually<br />

consolidated its position <strong>in</strong> the CRO<br />

<strong>in</strong>dustry.<br />

When Accutest had started mak<strong>in</strong>g its<br />

mark, there were not many USFDA<br />

accredited laboratories available to<br />

outsource cl<strong>in</strong>ical research<br />

requirements for pharma organisations.<br />

Pharma market was open<strong>in</strong>g up and<br />

Indian Pharma Industry was gear<strong>in</strong>g up<br />

to launch their products <strong>in</strong> developed<br />

countries like US and Europe. Thus, <strong>in</strong><br />

2004, the company got the approval<br />

from USFDA. After this <strong>in</strong>itial step,<br />

there was no look<strong>in</strong>g back whether it<br />

was to add new facilities, <strong>in</strong>crease<br />

capacities or subsequent audits and<br />

approvals from prom<strong>in</strong>ent regulatory<br />

bodies across the world.<br />

Under steady leadership of Dr Sawant,<br />

Accutest kept on <strong>in</strong>novat<strong>in</strong>g itself by<br />

add<strong>in</strong>g range of diverse services.<br />

Accutest and its leadership have<br />

consistently been recognized for its<br />

success and constant good work with<br />

prestigious awards and accolades<br />

throughout its journey of 21 years so<br />

far.<br />

32<br />

| June 2019 |


Eclectic Services<br />

Accutest provides services across<br />

various verticals like<br />

Bioavailability/Bioequivalence<br />

(BA/BE) studies for Generic Industry,<br />

Cl<strong>in</strong>ical Development Services (CDS)<br />

for New Chemical Entities, and Bioanalytical<br />

Services to Biologics/Biosimilar<br />

drug molecules. Speak<strong>in</strong>g<br />

about all that they offer to the clients,<br />

Dr. Sawant says, “At Accutest, we<br />

assist Pharma <strong>in</strong>dustries <strong>in</strong> their drug<br />

development life cycle by evaluat<strong>in</strong>g its<br />

safety, efficacy, ADME character, and<br />

quality aspect before the product is<br />

certified as appropriate for market<strong>in</strong>g.<br />

As a CRO, we become a part of the<br />

pharmaceutical organizations <strong>in</strong> their<br />

research program to evaluate<br />

medic<strong>in</strong>es for their quality and test on<br />

human population for the safety,<br />

effectiveness, and blood levels of the<br />

drug after they are consumed.”<br />

Accutest has undoubtedly emerged to<br />

be the preferred CRO for first-to-file<br />

studies. <strong>The</strong> company also focuses on<br />

Phase II-IV cl<strong>in</strong>ical trials services for<br />

drug development companies <strong>in</strong> India<br />

and abroad. It conducts cl<strong>in</strong>ical trials<br />

as per Standard Operat<strong>in</strong>g Procedures<br />

(SOPs) developed <strong>in</strong>-house, <strong>in</strong><br />

accordance with ICH GCP guidel<strong>in</strong>es<br />

and Indian GCP to accomplish and<br />

efficiently cater to requirements of its<br />

clients.<br />

Accutest Biologics, its subsidiary, is a<br />

one-stop solution for analytical and<br />

bio-analytical services from early stage<br />

characterization to the late stage<br />

cl<strong>in</strong>ical evaluation of biologics.<br />

Bioanalytical services <strong>in</strong>clude<br />

Pharmacok<strong>in</strong>etics, Pharmacodynamics,<br />

and Immunogenicity assessment of<br />

biologics, bio-therapeutics, biosimilars,<br />

vacc<strong>in</strong>es, and non-biological complex<br />

drugs us<strong>in</strong>g high-end assay formats<br />

like ELISA, MSD, and GYROS. It also<br />

provides <strong>in</strong> vitro activity/potency and<br />

bioassays services for evaluat<strong>in</strong>g the<br />

biological activities besides toxic<br />

k<strong>in</strong>etics and related services.<br />

What sets It Apart?<br />

Be<strong>in</strong>g <strong>in</strong> cl<strong>in</strong>ical research field for 21<br />

years now, Accutest is sett<strong>in</strong>g a niche<br />

<strong>in</strong> the <strong>in</strong>dustry with its unmatched<br />

expertise and services. <strong>The</strong> success<br />

stories of Accutest and accreditations<br />

from global regulators, like US FDA,<br />

WHO, EMA, ANVISA, DCGI, MCC<br />

and other prom<strong>in</strong>ent authorities, stand<br />

as a testament to its unwaver<strong>in</strong>g<br />

commitment to <strong>in</strong>ternational quality<br />

standards and operat<strong>in</strong>g procedures.<br />

Recently, the company received the<br />

prestigious OECD GLP certification by<br />

NGCMA. Accutest is the first and only<br />

<strong>in</strong>dependent biologics test<strong>in</strong>g facility <strong>in</strong><br />

India to be honored with this<br />

<strong>in</strong>ternational accreditation. <strong>The</strong><br />

company constantly strives to re<strong>in</strong>vent<br />

itself, along with provid<strong>in</strong>g advanced<br />

services to its clients.<br />

Incredible Team<br />

Accutest takes great pride <strong>in</strong> its<br />

dynamic team, which understands<br />

customer requirements and gives<br />

optimal solutions. Dr. Sawant asserts,<br />

“We have a rich pool of well qualified<br />

and dedicated professionals, these are<br />

our assets. <strong>The</strong>ir rich experience and<br />

<strong>in</strong>volvement dur<strong>in</strong>g clients’ drug<br />

development program gives clients the<br />

confidence to outsource their cl<strong>in</strong>ical<br />

development needs. Timely delivery,<br />

our regulatory history, global reach,<br />

staff and our ability to work hand-<strong>in</strong>hand<br />

with the clients are some of our<br />

value propositions which set us apart<br />

from other competitors <strong>in</strong> the market.”<br />

Perfect R&D Partner<br />

Accutest is the partner of choice for<br />

generic drug manufacturers look<strong>in</strong>g to<br />

execute BA/BE studies with a high<br />

degree of quality and speed, at<br />

competitive prices. It has one of the<br />

largest data banks of 41,000+<br />

volunteers along with strong regulatory<br />

track records. <strong>The</strong> company’s state-ofthe-art<br />

<strong>in</strong>frastructure comprises of<br />

more than 400 beds, 38 LCMS-MS,<br />

and 700+ validated methods, enabl<strong>in</strong>g<br />

it to serve the clients with ease and<br />

quality. Acutest is render<strong>in</strong>g numerous<br />

benefits to its clients by cater<strong>in</strong>g to<br />

their complete, complex, and cross<br />

functional service requirements, under<br />

one roof with ease and expertise.<br />

‘‘ We offer an<br />

umbrella<br />

contract-based<br />

R&D services to<br />

our <strong>in</strong>dustry<br />

partners with a<br />

focus on quality<br />

and quick<br />

turnaround<br />

time<br />

‘‘<br />

| June 2019 | 33


Sp<strong>in</strong>eMark<br />

Corporation<br />

Transform<strong>in</strong>g Care Delivery Through<br />

Exceptional Care Services<br />

Sp<strong>in</strong>e <strong>in</strong>juries can be life alter<strong>in</strong>g<br />

and fatal <strong>in</strong> some cases. A great<br />

deal of perseverance and<br />

dedicated physical exercise is required<br />

to recover from sp<strong>in</strong>al <strong>in</strong>juries or<br />

surgeries. One such organization that is<br />

built around the needs of sp<strong>in</strong>e patients<br />

is Sp<strong>in</strong>eMark Corporation.<br />

Headquarter <strong>in</strong> San Diego, California,<br />

the company was established <strong>in</strong> 2011.<br />

Its patient-centric, transparent, and<br />

outcome-accountable services are what<br />

set it apart from its counterparts.<br />

<strong>The</strong> model of Sp<strong>in</strong>eMark’s sp<strong>in</strong>e<br />

centers of excellence are built around<br />

the needs of patients. <strong>The</strong> centers<br />

advocate for their patients and cater to<br />

the patients’ needs. <strong>The</strong> service<br />

protocols for patients <strong>in</strong>clude an<br />

<strong>in</strong>tegrated delivery system with a team<br />

of multispecialty providers, <strong>in</strong>clud<strong>in</strong>g<br />

personnel for diagnostic, operative,<br />

non-operative care, and holistic or<br />

conservative care modalities.<br />

Every Sp<strong>in</strong>eMark center starts with the<br />

physician and surgeon champions, who<br />

recognize the need for collaboration, a<br />

facility partner, and algorithms from<br />

the least to most <strong>in</strong>vasive type of care.<br />

This is based on failure along a<br />

cascad<strong>in</strong>g cha<strong>in</strong> of modalities, team<br />

conference staff<strong>in</strong>g of patients, cl<strong>in</strong>ical<br />

research activities, and a cl<strong>in</strong>ical<br />

Marcy T. Rogers<br />

President & Chief Executive Officer<br />

operat<strong>in</strong>g committee of four or more<br />

members of the team who provide<br />

cl<strong>in</strong>ical oversight.<br />

A nurse navigator and an <strong>in</strong>take<br />

coord<strong>in</strong>ator are recruited to provide<br />

coord<strong>in</strong>ation of care and follow up. A<br />

medical “gatekeeper” is recruited to<br />

manage new and established patients<br />

through their care needs and the system<br />

itself. Outcomes data and process<br />

measures as well as transparency are<br />

the key components of Sp<strong>in</strong>eMark’s<br />

system for patient care.<br />

Thought Leadership<br />

Marcy T. Rogers, M.Ed., is the<br />

President and Chief Executive<br />

Officer of Sp<strong>in</strong>eMark. Rogers has built<br />

her executive career <strong>in</strong> the healthcare<br />

<strong>in</strong>dustry through the development of<br />

niche surgical centers of excellence<br />

fueled by <strong>in</strong>novation and cl<strong>in</strong>ical<br />

research. A proven leader, she has built<br />

trust and rapport with physicians,<br />

hospitals, ambulatory surgery centers,<br />

and medical device manufacturers <strong>in</strong><br />

sp<strong>in</strong>e, orthopedics, biologics, and<br />

<strong>in</strong>terventional pa<strong>in</strong>. She has dedicated<br />

over 30 years of her life to deliver<strong>in</strong>g<br />

results.<br />

Through alliances, partnerships, and<br />

collaborations <strong>in</strong> the field of sp<strong>in</strong>al<br />

care, Rogers is gett<strong>in</strong>g th<strong>in</strong>gs done. Her<br />

dest<strong>in</strong>ation center model <strong>in</strong>tegrates and<br />

aligns stakeholders <strong>in</strong> the delivery of<br />

sp<strong>in</strong>e services, and she has successfully<br />

demonstrated solid f<strong>in</strong>ancial results as<br />

well as strong returns on <strong>in</strong>vestment<br />

for the hospitals, ambulatory surgery<br />

centers, and physician groups she has<br />

managed and counseled. She has<br />

consulted and worked with over 300<br />

hospitals and surgery centers on their<br />

musculoskeletal and neurological<br />

service l<strong>in</strong>es, formation of new centers,<br />

or expand<strong>in</strong>g facilities on its campuses<br />

<strong>in</strong> the US and abroad.<br />

Through her recognitions and<br />

endeavors, Rogers has established<br />

herself as a key op<strong>in</strong>ion leader <strong>in</strong> the<br />

field of sp<strong>in</strong>e among her clients,<br />

professional colleagues, and peers.<br />

<strong>The</strong> Vision of Sp<strong>in</strong>eMark<br />

<strong>The</strong> company strives to create a new<br />

standard of care for patients suffer<strong>in</strong>g<br />

from back pa<strong>in</strong>. “Currently there is no<br />

standard of care and the field of sp<strong>in</strong>e<br />

is fragmented at best with many<br />

different providers label<strong>in</strong>g themselves<br />

as sp<strong>in</strong>e experts as naturopaths,<br />

chiropractors, sp<strong>in</strong>e surgeons,<br />

<strong>in</strong>terventional pa<strong>in</strong> specialists,<br />

neurologists, et al.,” says Rogers.<br />

Sp<strong>in</strong>eMark is work<strong>in</strong>g towards<br />

build<strong>in</strong>g a network of dozens of sites<br />

34<br />

| June 2019 |


across the US and outside the US,<br />

<strong>in</strong>clud<strong>in</strong>g <strong>in</strong> Kuwait, Ch<strong>in</strong>a, and<br />

Europe. <strong>The</strong> company works towards<br />

standardiz<strong>in</strong>g the treatment of patients<br />

suffer<strong>in</strong>g from back pa<strong>in</strong> via a<br />

treatment protocol, quality service,<br />

positive outcomes, efficacy, and quality<br />

data.<br />

<strong>The</strong> organization’s values are always<br />

focused on the least <strong>in</strong>vasive “do no<br />

harm” approach to treat<strong>in</strong>g patients.<br />

This starts with 4-6 weeks of<br />

conservative care, which <strong>in</strong>cludes<br />

<strong>in</strong>terventional pa<strong>in</strong> procedures to<br />

m<strong>in</strong>imally <strong>in</strong>vasive sp<strong>in</strong>e surgery.<br />

<strong>The</strong>se are the first choices if supported<br />

by the patient’s condition. “We want<br />

the patient to have the right procedure<br />

at the right time by the right doctor(s).<br />

That is our mantra,” asserts Rogers.<br />

Dist<strong>in</strong>ctive Services and Solutions<br />

Sp<strong>in</strong>eMark is the premier global sp<strong>in</strong>e<br />

service company for the development<br />

of Sp<strong>in</strong>e Dest<strong>in</strong>ation Centers and Sp<strong>in</strong>e<br />

Research Organizations <strong>in</strong> partnership<br />

with medical professionals, hospitals,<br />

and <strong>in</strong>dustry medical manufacturers.<br />

Its centers provide excellent medical,<br />

operative, non-operative, and ancillar<br />

services, all delivered under one<br />

<strong>in</strong>tegrated delivery system. This<br />

reduces patient chaos, cost, and<br />

duplication of procedures.<br />

<strong>The</strong> establishment of cl<strong>in</strong>ical research<br />

units at each site, as well as<br />

ma<strong>in</strong>stream<strong>in</strong>g m<strong>in</strong>imally <strong>in</strong>vasive<br />

sp<strong>in</strong>e surgery procedures at numerous<br />

sites of the organization, is the most<br />

dist<strong>in</strong>ct feature of its service. <strong>The</strong><br />

company’s model is built on diseasebased<br />

medical management and is<br />

measured for quality.<br />

Communication is the key to success,<br />

believes Rogers. Thanks to the use of a<br />

nurse navigator and <strong>in</strong>take coord<strong>in</strong>ator,<br />

patients never fall through the cracks.<br />

Speak<strong>in</strong>g about the nurse navigator<br />

support system, Rogers says, “We<br />

support patients through our services,<br />

model, management of their dist<strong>in</strong>ct<br />

needs throughout the course of<br />

treatment by us<strong>in</strong>g nurse navigators to<br />

guide them through various phases of<br />

care.” Sp<strong>in</strong>eMark also often l<strong>in</strong>ks new<br />

patients with exist<strong>in</strong>g patients who<br />

have been treated by its team and have<br />

similar pretreatment or surgical issues.<br />

Hence, its post-operative patients are<br />

the greatest advocates for prov<strong>in</strong>g<br />

Sp<strong>in</strong>eMark’s model.<br />

Sp<strong>in</strong>eMark holds itself accountable<br />

through outcomes and quality data<br />

collection, transparency, and a focused<br />

approach on the identification of the<br />

somatic orig<strong>in</strong> of the pa<strong>in</strong>. Diagnosis is<br />

key; surgery is always the last resort.<br />

Bright Future for Sp<strong>in</strong>eMark<br />

“We are look<strong>in</strong>g to expand our sites<br />

throughout the US and abroad, with<br />

centers locally, regionally, and<br />

nationally,” says Rogers. <strong>The</strong>re are 1.8<br />

billion people disabled by back pa<strong>in</strong>.<br />

<strong>The</strong> company wants to be a resource to<br />

as many of these patients as possible.<br />

Advancement <strong>in</strong> Sp<strong>in</strong>e Treatment<br />

“<strong>The</strong> new development <strong>in</strong> sp<strong>in</strong>e<br />

treatment has been ‘through cl<strong>in</strong>ical<br />

research’,” asserts Rogers. M<strong>in</strong>imally<br />

<strong>in</strong>vasive sp<strong>in</strong>e surgery techniques are<br />

f<strong>in</strong>ally tak<strong>in</strong>g the field by storm and are<br />

becom<strong>in</strong>g ma<strong>in</strong>stream. “A few years<br />

ago, this was not the case,” she<br />

cont<strong>in</strong>ues. Technological advances <strong>in</strong><br />

robotics, <strong>in</strong>strumentation, fixation, and<br />

implants comb<strong>in</strong>ed with cell and gene<br />

therapy biologics is chang<strong>in</strong>g the<br />

treatment of sp<strong>in</strong>al conditions.<br />

Today, one can perform complex sp<strong>in</strong>e<br />

procedures - both lumbar and cervical<br />

fusion - arthroscopically, reduc<strong>in</strong>g<br />

rehabilitation and recovery, and<br />

allow<strong>in</strong>g patients to return to normal<br />

function <strong>in</strong> little time. Sp<strong>in</strong>e treatment<br />

is becom<strong>in</strong>g more holistic and<br />

non-<strong>in</strong>vasive with the advancement <strong>in</strong><br />

technology. Sp<strong>in</strong>eMark, with its<br />

cl<strong>in</strong>ical research units, is mak<strong>in</strong>g sure<br />

it keeps up with the <strong>in</strong>novation.<br />

‘‘ Our diagnostic,<br />

conservative<br />

care, holistic,<br />

operative,<br />

non-operative<br />

care, and cl<strong>in</strong>ical<br />

research units<br />

are set up to<br />

participate,<br />

so that we<br />

are always<br />

advanc<strong>in</strong>g care<br />

through research<br />

‘‘<br />

| June 2019 | 35


36<br />

| June 2019 |


Novel Discoveries<br />

Top Health Tech<br />

I n n o vat i o n s I N 2 0 1 9 t h at a r e<br />

Break<strong>in</strong>g<br />

t<br />

h<br />

e<br />

Barriers<br />

“Every once <strong>in</strong> a while, a new technology, an old problem, and a big idea turn <strong>in</strong>to an <strong>in</strong>novation.”<br />

- Dean Kamen<br />

very day, new technologies are emerg<strong>in</strong>g. Humans are us<strong>in</strong>g all their bra<strong>in</strong>s to <strong>in</strong>vent someth<strong>in</strong>g new,<br />

Esometh<strong>in</strong>g unique, and someth<strong>in</strong>g that helps mank<strong>in</strong>d. With all the recent advancements, technology<br />

<strong>in</strong> the healthcare and medical sector has geared up as well. <strong>The</strong> embedd<strong>in</strong>g of articial <strong>in</strong>telligence<br />

and IoT is now done extensively <strong>in</strong> the healthcare sector. Various new techniques are be<strong>in</strong>g <strong>in</strong>vented that<br />

help society to grow <strong>in</strong> a self-sufcient manner. From electric cars to generat<strong>in</strong>g electricity through nuclear<br />

energy, humans are advanc<strong>in</strong>g <strong>in</strong> all aspects.<br />

Health has always been on the top priority for a person so it is essential that he/she is treated with<strong>in</strong> time<br />

and with perfection. Due to <strong>in</strong>novative m<strong>in</strong>ds, there have been various upgrades <strong>in</strong> the eld. <strong>The</strong>re are<br />

treatments for many diseases and disorders which were not thought of a few years ago. Various <strong>in</strong>struments<br />

and facilities have become affordable to the healthcare service providers like hospitals and cl<strong>in</strong>ics.<br />

Researchers are try<strong>in</strong>g hard to provide everyth<strong>in</strong>g for better treatment of the public. Various medic<strong>in</strong>es have<br />

been used to treat diseases successfully and many diseases have already been eradicated from the earth.<br />

New types of equipment have helped the doctors <strong>in</strong> various complicated surgeries. In the follow<strong>in</strong>g year,<br />

there have been many new <strong>in</strong>novations for the betterment of the lives of people. Here are a few notable<br />

technological <strong>in</strong>novations:<br />

| June 2019 | 37


3-D PRINTING<br />

Surgeries are very complicated and <strong>in</strong>volve a lengthy process. Precision is<br />

very important and practic<strong>in</strong>g it beforehand is highly crucial. Doctors use<br />

3-D models for practic<strong>in</strong>g the surgeries. <strong>The</strong> 3-D pr<strong>in</strong>t<strong>in</strong>g mach<strong>in</strong>e<br />

models are made <strong>in</strong> accordance with the patient’s anatomy. In recent<br />

times, few important developments <strong>in</strong> 3-D pr<strong>in</strong>t<strong>in</strong>g have come <strong>in</strong> external<br />

prosthetics, cranial or orthopedic implants, and custom airway stents. It<br />

has also been helpful <strong>in</strong> surgical plann<strong>in</strong>g as well <strong>in</strong> complex open heart<br />

surgeries. <strong>The</strong>re are researches be<strong>in</strong>g carried out to pr<strong>in</strong>t human tissue<br />

that will make organ transplants possible.<br />

ARTIFICIAL INTELLIGENCE<br />

<strong>The</strong> biggest problem <strong>in</strong> mak<strong>in</strong>g a drug for a rare disease is the huge data of<br />

the patients and their compliance. Many researchers and pharmaceutical<br />

companies are tak<strong>in</strong>g the help of AI to organize the data from the medical<br />

records and nd commonalities with the diseases. AI has been a huge plus<br />

po<strong>in</strong>t for doctors and general practitioners as it helps to collect and nd the<br />

data of the patients whenever required. This technology is transform<strong>in</strong>g all<br />

areas of the healthcare <strong>in</strong>dustry, from work process control and diagnostics to<br />

process automatization, productivity-enhanc<strong>in</strong>g, and enhancements <strong>in</strong><br />

diagnostics accuracy.<br />

RNA-BASED<br />

THERAPEUTICS<br />

Recently, RNA-based therapeutics are be<strong>in</strong>g used where RNA is modied or<br />

replaced before it forms <strong>in</strong>to a prote<strong>in</strong>. It allows the cl<strong>in</strong>icians to detect any<br />

genetic abnormality beforehand and treat the problem by replac<strong>in</strong>g it<br />

accord<strong>in</strong>gly with function<strong>in</strong>g or non-function<strong>in</strong>g prote<strong>in</strong>s. Advancement <strong>in</strong><br />

RNA therapeutics may even lead to solv<strong>in</strong>g the problems of rare diseases like<br />

Hunt<strong>in</strong>gton’s disease, neurologic disorders, and several forms of cancer.<br />

NEW IMMUNOTHERAPY<br />

TECHNIQUES<br />

Basically, immunotherapy is a treatment for cancer. In this type of<br />

treatment, white blood cells are <strong>in</strong>creased <strong>in</strong> the patient’s body so as to<br />

ght aga<strong>in</strong>st various diseases. A variety of experiments are be<strong>in</strong>g carried<br />

out <strong>in</strong> comb<strong>in</strong>ation with jo<strong>in</strong>t therapy and eng<strong>in</strong>eered T-cells that can prove<br />

to be effective aga<strong>in</strong>st a wide range of tumor cells.<br />

38<br />

| June 2019 |


ROBOTIC SURGERY<br />

Robotics has been adm<strong>in</strong>istered <strong>in</strong> various medical treatments. Nanobots are<br />

be<strong>in</strong>g adm<strong>in</strong>istered <strong>in</strong> bloodstreams of the patients that can diagnose and<br />

prevent diseases. Movement disabilities can be monitored by exoskeletons<br />

with the assistance of physical therapy. One of the major <strong>in</strong>novations of 2019<br />

is robotic surgery. Now, robots can be useful <strong>in</strong> perform<strong>in</strong>g various<br />

procedures dur<strong>in</strong>g surgery. A robot can perform tasks and provide medical<br />

assistance like giv<strong>in</strong>g an <strong>in</strong>jection and gather<strong>in</strong>g <strong>in</strong>formation. <strong>The</strong>re are<br />

support<strong>in</strong>g robots that manage to courier medical <strong>in</strong>struments and other<br />

related supplies.<br />

TELEHEALTH<br />

With everyth<strong>in</strong>g be<strong>in</strong>g digitized, there was a need to monitor a person’s health<br />

through digital services. Now, this has become possible. Doctors can monitor<br />

their patient's health even from a distance. <strong>The</strong> doctor can make a primary<br />

conclusion from analyz<strong>in</strong>g the report that is generated digitally. This way, the<br />

expenses of the patients are reduced to a great extent.<br />

HEALTH WEARABLE<br />

As it is said <strong>in</strong> a famous quote, ‘Precaution is better than cure’, it is important<br />

to ma<strong>in</strong>ta<strong>in</strong> a healthy life. People have started to understand that be<strong>in</strong>g<br />

healthy is really helpful <strong>in</strong> avoid<strong>in</strong>g any future diseases or disorders. <strong>The</strong>re<br />

are various companies that have <strong>in</strong>vented unique health wearable that help a<br />

person track his/her own health. One can monitor the heart rate, glucose<br />

level, physical activity, and also sleep tim<strong>in</strong>gs with these. This way, the person<br />

can analyze where he is lack<strong>in</strong>g and work on it, accord<strong>in</strong>gly.<br />

GENOMICS<br />

A person’s identity is from his/her genes. Even, what disease can affect a person<br />

is decided by the genetic make of the body. Biotech companies have come up<br />

with technology that can be helpful <strong>in</strong> decod<strong>in</strong>g <strong>in</strong>dividual genomic makeup<br />

and aid <strong>in</strong> enhanc<strong>in</strong>g the diagnosis and treatment for various genetic and nongenetic<br />

diseases. <strong>The</strong>se companies are further try<strong>in</strong>g to develop a personalized<br />

treatment with the help of this technology. In 2017, CRISPR, a gene edit<strong>in</strong>g tool<br />

was used to successfully edit human embryos <strong>in</strong> which hypertrophic<br />

cardiomyopathy, a complex heart disease, with<strong>in</strong> 42 embryos was eradicated.<br />

Technology has been prov<strong>in</strong>g to be work<strong>in</strong>g hand <strong>in</strong> hand with the healthcare <strong>in</strong>dustry for the betterment of the<br />

quality of care provided. Every day, the world witness’s new developments and with this mank<strong>in</strong>d is mov<strong>in</strong>g towards<br />

more accurate and affordable treatment options.<br />

- Shambhavi Mhetre, Editor<br />

| June 2019 | 39

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!